Bosutinib. Dual Src and Abl kinase inhibitor treatment of solid tumors treatment of CML and Ph+ all

Drugs of the Future

Volumn 32, Issue 6, 2007, Pages 481-490

  Boschelli, Diane H ^a   Boschelli, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BOSUTINIB; DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR;

ARTICLE; BONE METASTASIS; BRAIN ISCHEMIA; BREAST METASTASIS; BREAST TUMOR; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL TUMOR; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG EDEMA; NAUSEA; NONHUMAN; PLEURA EFFUSION; RASH; TUMOR REGRESSION; XENOGRAFT;

EID: 34547744408     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.06.1107656     Document Type: Article

References (64)

1. Boschelli, D.H., Ye, F., Wang, Y.D. et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001, 44(23): 3965-77.
2. Boschelli, D.H., Wang, Y.D., Johnson, S. et al. 7-Alkoxy-4- phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J Med Chem 2004, 47(7): 1599-601.
3. Sutherland, K.W., Feigelson, G.B., Boschelli, D.H., Blum, D.M., Strong, H.L. (Wyeth Corp.). Process for the preparation of 4-amino-3- quinolinecarbonitriles and 7-aminothieno[3,2-b]pyridine-6-carbonitriles. US 2005043537, WO 2005019201.
4. Tesconi, M.S., Feigelson, G., Strong, H., Wen, H. (Wyeth Corp.). Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3- (4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile. US 2007015767, WO 2007005462.
5. Courtneidge, S.A. Role of Src in signal transduction pathways. Biochem Soc Trans 2002, 30(2): 11-7.
6. Frame, M.C. Src in cancer: Deregulation and consequences for cell behavior. Biochim Biophys Acta 2002, 1602(2): 114-30.
7. Summy, J.M., Gallick, G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22(4): 337-58.
8. Talamonti, M.S., Roh, M.S., Curley, S.A., Gallick, G.E. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993, 91(1): 53-60.
9. Ito, H., Gardner-Thorpe, J., Zinner, M.J., Ashley, S.W., Whang, E.E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003, 134(2): 221-6.
10. Wiener, J.R., Windham, T.C., Estrella, V.C. et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003, 88(1): 73-9.
11. Myoui, A., Nishimura, R., Williams, P.J. et al. C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003, 63(16): 5028-33.
12. Matsumoto, T., Jiang, J., Kiguchi, K. et al. Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. Cancer Res 2003, 63(16): 4819-28.
13. Summy, J.M., Gallick, G.E. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006, 12(5): 1398-401.
14. Zhang, Q., Thomas, S.M., Xi, S. et al. Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004, 64(17): 6166-73.
15. Xi, S., Zhang, Q., Dyer, K.F. et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003, 278(34): 31574-83.
16. Mitra, S.K., Schlaepfer, D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18(5): 516-23.
17. Avizienyte, E., Wyke, A.W., Jones, R.J. et al. Src-induced deregulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002, 4(8): 632-8.
18. Irby, R.B., Yeatman, T.J. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002, 62(9): 2669-74.
19. Coluccia, A.M.L., Benati, D., Dekhil, H., De Filippo, A., Lan, C., Gambacorti-Passerini, C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of β-catenin and its nuclear signaling. Cancer Res 2006, 66(4): 2279-86.
20. Eliceiri, B.P., Paul, R., Schwartzberg, P.L., Hood, J.D., Leng, J., Cheresh, D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999, 4: 915-24.
21. Criscuoli, M.L., Nguyen, M., Eliceiri, B.P. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005, 105(4): 1508-14.
22. Capdeville, R., Buchdunger, E., Zimmermann, J., Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1(7): 493-502.
23. Lydon, N.B., Druker, B.J. Lessons learned from the development of imatinib. Leuk Res 2004, 28(Suppl. 1): S29-38.
24. Kalidas, M., Kantarjian, H., Talpaz, M. Chronic myelogenous leukemia. JAMA - J Am Med Assoc 2001, 286(8): 895-8.
25. Goldman, J.M., Druker, B.J. Chronic myeloid leukemia: Current treatment options. Blood 2001, 98(7): 2039-42.
26. Ribeiro, R., Abromowitch, M., Raimondi, S., Murphy, S., Behm, F., Williams, D. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987, 70(4): 948-53.
27. Druker, B.J., Guilhot, F, O'Brien, S.G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Eng J Med 2006, 355(23): 2408-17.
28. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531): 876-80.
29. Shah, N., Sawyers, C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemia. Oncogene 2003, 22: 7389-95.
30. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., Kuriyan, J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289(5486): 1938-42.
31. Nagar, B., Bornmann, W.G., Pellicena, P. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62(15): 4236-43.
32. Talpaz, M., Shah, N.P., Kantarjian, H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Eng J Med 2006, 354(24): 2531-41.
33. Shah, N.P., Tran, C, Lee, F.Y., Chen, P., Norris, D., Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682): 399-402.
34. Lombardo, L.J., Lee, F.Y., Chen, P. et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47(27): 6658-61.
35. Boschelli, D.H., Wang, Y.D., Ye, F. et al. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 2001, 44(5): 822-33.
36. Puttini, M., Coluccia, A.M.L., Boschellli, F. et al. In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66(23): 11314-22.
37. Golas, J.M., Lucas, J., Etienne, C. et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005, 65(12): 5358-64.
38. Jallal, H., Valentino, M.-L., Chen, G., Boschelli, F, Ali, S., Rabbani, S.A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007, 67(4): 1580-8.
39. Boschelli, F., Arndt, K., Etienne, C. et al. Inhibition of colon tumor xenografts in nude mice by oral administration of SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3874.
40. Boschelli, F., Golas, J.M., Golas, J., Lucas, J., Discafani, C., Arndt, K., Boschelli, D. A novel, potent inhibitor of Src family kinases with in vivo activity. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4574.
41. Boschelli, F.C. (Wyeth Corp.). 4-Anilino-3-quinolinecarbonitriles for the treatment of cancer. US 2007010527, WO 2007001839.
42. Zhang, J., Kalyankrishn, S., Wislez, M. et al. Src-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007, 170(1): 366-76.
43. Boschelli, F., Chen, L., Tkach, D. et al. Re-establishment of cell-cell contacts and beta-catenin membrane localization in Colo205 colorectal tumor cells treated with the Src inhibitor bosutinib (SKI-606). Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 5634.
44. Vultur, A.M., Buettner, R., Kowolik, C., Smith, D., Boschelli, F., Jove, R. SKI-606, a novel Src kinase inhibitor, blocks migration and invasion of human breast cancer cells. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 3251.
45. Golas, J.M., Arndt, K., Etienne, C. et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63(2): 375-81.
46. Quintás-Cardama, A., Manshouri, T., Tong, W., Kantarjian, H., Cortes, J., Garcia-Manero, G. The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 1825.
47. Donato, N.J., Wu, J.Y., Talpaz, M., Dutia, M., Ye, F., Boschelli, D., Boschelli, F. Novel tyrosine kinase inhibitors suppress BCR-ABL signaling and induce apoptosis in STI-571 sensitive and resistant CML cells. Blood 2002, 100(11, Part 1): Abst 1434.
48. Mancini, M., Brusa, G., Zuffa, E. et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk Res 2007, 31(7): 979-87.
49. Coluccia, A.M.L., Vacca, A., Dunach, M. et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007, 26(5): 1456-66.
50. Boschelli, D.H. Bcr-Abl kinase inhibitors. In: Topics in Medicinal Chemistry: Cancer, Vol. 1. Bradbury, R. (Ed.). Springer, Heidelberg, 2007, 407-44.
51. Weis, S., Cui, J., Barnes, L., Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004, 167(2): 223-9.
52. Soriano, P., Montgomery, C., Geske, R., Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64: 693-702.
53. Darnay, B.G., Price, J.E., Poblenz, A., Talpaz, M. (Univ. Texas). Inhibition of osteolytic lesions by quinolinecarbonitrile derivative Src kinase inhibitors. US 2007004748, WO 2006138590.
54. Paul, R., Zhang, Z G., Eliceiri, B.P. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 2001, 7(2): 222-7.
55. Zaleska, M.M., Liang, S., Xiao, Y. et al. Targeting acute focal stroke with a novel SRC kinase inhibitor SKI-606. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 741.14.
56. Gonzales, C., Xiao, Y., Liang, S. et al. Expanded therapeutic window for SKI-606, a novel Src kinase inhibitor, in rat transient focal ischemia. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 741.15.
57. Pong, K., Xiao, Y., Zaleska, M.M. SKI-606, a novel inhibitor of SRC kinase, blocks VEGF-induced activity in endothelial cells and vascular permeability following stroke. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 741.16.
58. Liang, S., Chen, Y., Zaleska, M.M. SKI-606, a novel Src kinase inhibitor, improves long-term sensorimotor recovery after permanent ischemia. 33rd Annu Meet Soc Neurosci (Nov 8-12, New Orleans) 2003, Abst 741.17.
59. Gonzales, C., Chen, Y., Zaleska, M.M. Treatment with a novel Src kinase inhibitor reduces edema and functional deficits in the rat intracerebral hemorrhage model. 34th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 103.3.
60. Weis, S., Shintani, S., Weber, A. et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004, 113(6): 885-94.
61. Konig, H., Sindhu, S.K., Boschelli, F., Holyoake, T.L., Forman, S.J., Bhatia, R. The dual Src/Abl kinase inhibitor SKI-606 effectively inhibits Bcr-Abl kinase activity and reduces proliferation of CML primitive progenitor cells. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 1370.
62. Grafone, T., Mancini, M., Ottaviani, E. et al. A novel 4-anilino-3-quinolinecarbonitrile dual Src and Abl kinase inhibitor (SKI- 606) has in vitro activity on CML Ph+blast cells resistant to imatinib. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5984.
63. Renzulli, M., Grafone, T., Taccioli, C. et al. Gene expression profile in the CML cell line K562 treated with SKI-606, a dual inhibitor of Src/Abl kinases. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 4870.
64. Cortes, J., Kantarjian, H.M., Baccarani, M. et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood [48th Annu Meet Am Soc Hematol (Dec 9-12, Orlando) 2006] 2006, 108(11): Abst 168.